IFF delivered a solid fourth quarter performance in 2025, with reported net sales of $2.59 billion and adjusted operating EBITDA of $437 million. The company saw comparable currency neutral sales increase by 1% and adjusted operating EBITDA increase by 7%, driven by productivity gains. Strategic initiatives included the launch of a sale process for the Food Ingredients segment.

IFF delivered $2.69 billion in revenue with adjusted EPS of $1.05. Despite a revenue drop, net income remained positive at $40 million. Adjusted EBITDA was $519 million, showing solid productivity gains, especially in the Scent and Taste segments.

IFF delivered a strong second quarter in 2025 with reported net sales of $2.76 billion and a significant increase in net income to $612 million, up 256% year-over-year. The company achieved an EPS of $2.38 and a non-GAAP EPS of $1.15, while also reducing its net debt to credit adjusted EBITDA to 2.5x, ahead of its target. Strategic portfolio reshaping continued with the closing of Pharma Solutions and Nitrocellulose divestitures and an announced agreement to sell its soy crush, concentrates, and lecithin business.

IFF posted a $1.02B net loss in Q1 2025, driven by a $1.15B impairment charge. However, adjusted EPS and EBITDA were strong, reflecting volume growth and productivity gains.

IFF's Q4 2024 revenue increased by 3% YoY to $2.77 billion, driven by broad-based growth across all divisions. However, the company reported a net loss of $46 million, with an operating margin of 17.0%, reflecting reinvestments and cost pressures. Adjusted EPS was $0.97.

IFF reported a 4% increase in net sales to $2.93 billion for the third quarter of 2024. Volume grew high-single digits and improved across all businesses. Adjusted EPS excluding amortization was $1.04 per diluted share, a 17% increase. The company is increasing its full year 2024 financial guidance.

IFF reported a slight decrease in sales but a significant improvement in profitability for Q2 2024. Sales were $2.89 billion, a 1% decrease year-over-year, but comparable currency neutral sales increased by 7%. Adjusted operating EBITDA improved 22% to $588 million, and adjusted EPS excluding amortization was $1.16. The company is raising its full-year sales and adjusted operating EBITDA guidance.

IFF reported a 4% decrease in net sales to $2.90 billion, but comparable currency neutral sales increased by 5%. The company's adjusted operating EBITDA improved by 20% on a comparable basis, reaching $578 million. Reported EPS was $0.23, while adjusted EPS ex amortization was $1.13. The company has raised its full year guidance.

IFF reported a decrease in net sales for Q4 2023, but experienced growth in Scent and Health & Biosciences segments. The company faced a significant loss before taxes due to a non-cash goodwill impairment charge. However, adjusted operating EBITDA increased, driven by pricing and productivity gains.

IFF reported a decrease of 8% in reported net sales, totaling $2.82 billion. However, the company's volume performance improved across most businesses, and pricing remained strong. Adjusted operating EBITDA was $506 million, and adjusted EPS excluding amortization was $0.89 per diluted share. The company is on track to achieve its full-year 2023 sales guidance and expects adjusted operating EBITDA to be at the mid to high-end of the previously announced range.

IFF reported flat sales of $2.93 billion compared to the prior-year period, with a 4% decrease on a comparable currency-neutral basis. Growth in Scent and Pharma Solutions was offset by softness in Nourish and Health & Biosciences. Adjusted operating EBITDA was $510 million, impacted by lower volumes and a one-time inventory write-down. The company is focusing on portfolio optimization and operational improvements.

IFF's first quarter 2023 sales were $3.03 billion, flat versus the prior-year period. Adjusted EPS excluding amortization was $0.87 per diluted share. The company expects full year 2023 sales to be approximately $12.3 billion and adjusted operating EBITDA of approximately $2.34 billion.

IFF's Q4 2022 results showed a decrease in reported net sales, but an increase on a comparable currency neutral basis. The company focused on pricing and productivity to offset lower volumes. A refreshed growth-focused strategy was introduced to prioritize high-return businesses and drive long-term profitable growth.

IFF reported flat sales compared to the prior-year period, but experienced a significant loss before taxes due to a goodwill impairment charge. Adjusted operating EBITDA increased slightly on a currency neutral basis, driven by pricing actions and productivity gains. The company is proceeding cautiously due to challenging market conditions.

IFF reported a 7% increase in net sales to $3.31 billion for the second quarter of 2022. Adjusted operating EBITDA increased by 3% to $700 million. The company reaffirms its full-year 2022 financial guidance.

IFF reported a strong start to 2022, with net sales of $3.23 billion, a 31% increase compared to the prior year, and adjusted operating EBITDA of $702 million, a 23% increase. The company has increased its sales expectation to include incremental pricing actions to fully recover cost exposure and remains committed to delivering its full-year profit objective.

IFF reported strong fourth quarter results with a 139% increase in net sales to $3.03 billion, driven by the merger with Nutrition & Biosciences. Adjusted EPS excluding amortization was $1.10 per diluted share. The company is focused on pricing execution and cost discipline to improve operational performance amid inflationary pressures.

IFF reported strong third-quarter results with a 142% increase in reported net sales, driven by the merger with Nutrition & Biosciences (N&B). On a combined basis, sales increased by 12%. Adjusted operating EBITDA increased by 135%, and adjusted EPS excluding amortization was $1.47 per diluted share. However, profitability was impacted by macro supply-chain challenges and related cost increases.

IFF reported a strong second quarter performance with double-digit sales growth and a solid improvement in overall profitability. The company's synergy realization is on track, and the overall business performance underscores the strength and diversity of its portfolio.

IFF reported a net sales increase of 83% to $2.47 billion, driven by the merger with Nutrition & Biosciences (N&B). Adjusted operating EBITDA increased by 88% to $569 million, with an adjusted operating EBITDA margin of 23.1%. The company has also entered into an agreement to divest its fruit preparation business.

IFF reported a slight decrease in net sales for the fourth quarter, but saw growth excluding the impact of an additional week of sales in the previous year. The company's performance reflects the diversity of its portfolio and the essential nature of its products.

IFF reported flat sales of $1.27 billion compared to the prior year, with a 1% increase on a currency-neutral basis. The company experienced growth in Scent, while Fine Fragrance and Food Service were impacted by COVID-19. Reported EPS was $0.75, and adjusted EPS excluding amortization was $1.40. The company is progressing towards its combination with DuPont Nutrition and Biosciences, expecting completion in the first quarter of 2021.

IFF reported a 7% decrease in sales to $1.20 billion for the second quarter of 2020, impacted by COVID-19 related pressures, particularly in Fine Fragrance and Food Service. Despite the sales decline, the company highlighted robust cash flow and announced an increase in the quarterly dividend, reflecting confidence in the business's long-term strategy.

IFF reported a 4% increase in net sales to $1.35 billion for the first quarter of 2020. The company's EPS was $1.15, and adjusted EPS excluding amortization was $1.62. Strong performance in Scent and Taste segments drove the growth, while the company withdrew its full-year financial guidance due to COVID-19 related uncertainty.

IFF reported a 5% increase in net sales to $1.28 billion for the fourth quarter of 2019. Reported EPS was $0.70, while adjusted EPS ex amortization was $1.46. The company continued to achieve significant cost synergies from Frutarom and captured solid year one revenue synergies.